CMS Bends Knee Injection Code Policy Under Pressure From Genzyme
This article was originally published in The Pink Sheet Daily
Agency will pay for viscosupplement to treat osteoarthritic knees under four distinct codes, instead of lumping them into one as it had planned.
You may also be interested in...
Failed therapy is now on the back burner, as focus turns to approval and introduction of single-treatment viscosupplementation product Synvisc-One, company tells “The Pink Sheet” DAILY.
The high-profile COURAGE trial again raises the question of how soon stents should be placed in patients with coronary disease.